Pacira BioSciences (PCRX) Non-Current Debt (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Non-Current Debt of $367.7 million for Q1 2026, up 262.26% year-over-year from $101.5 million in Q1 2025, and down 1.22% quarter-over-quarter from $372.2 million in Q4 2025.
Pacira BioSciences (PCRX) Non-Current Debt (2010 - 2026) Analysis & Trends
Pacira BioSciences' Non-Current Debt history runs 10 years deep, the most recent figure standing at $367.7 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 262.26% year-over-year to $367.7 million; the TTM figure through Mar 2026 stood at $367.7 million (up 262.26% YoY), while the FY2025 annual figure was $372.2 million, down 36.41% from the prior year.
- Non-Current Debt for Q1 2026 stood at $367.7 million, down from $372.2 million in the prior quarter.
- The five-year high for Non-Current Debt was $689.5 million in Q4 2022, with the low at $97.8 million in Q2 2025.
- The 5-year median for Non-Current Debt is $309.8 million (2022), against an average of $281.6 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt plunged 61.93% in 2023, then jumped 262.26% in 2026.
- Pacira BioSciences' Non-Current Debt stood at $689.5 million in 2022, then declined by 24.23% to $522.4 million in 2023, then grew by 12.04% to $585.3 million in 2024, then plunged by 36.41% to $372.2 million in 2025, then dropped by 1.22% to $367.7 million in 2026.
- Business Quant data shows PCRX's Non-Current Debt at $367.7 million in Q1 2026, $372.2 million in Q4 2025, and $376.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.23 Bn | 43.26 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.82 Bn | 40.16 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.64 Bn | 30.96 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.38 Bn | 19.71 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.88 Bn | 17.99 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.96 Bn | 11.43 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Pacira BioSciences | 938.80 Mn | 687.77 Mn | 148.24 Mn | 363.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 363.12 Mn |
| Mar 31, 2026 | 367.66 Mn |
| Dec 31, 2025 | 372.19 Mn |
| Sep 30, 2025 | 376.72 Mn |
| Jun 30, 2025 | 97.83 Mn |
| Mar 31, 2025 | 101.49 Mn |
| Dec 31, 2024 | 585.32 Mn |
| Sep 30, 2024 | 107.02 Mn |
| Jun 30, 2024 | 109.75 Mn |
| Mar 31, 2024 | 112.48 Mn |
| Dec 31, 2023 | 522.44 Mn |
| Sep 30, 2023 | 117.97 Mn |
| Jun 30, 2023 | 134.82 Mn |
| Mar 31, 2023 | 137.53 Mn |
| Dec 31, 2022 | 689.47 Mn |
| Sep 30, 2022 | 309.85 Mn |
| Jun 30, 2022 | 318.34 Mn |
| Mar 31, 2022 | 326.83 Mn |
| Dec 31, 2021 | 335.26 Mn |
| Sep 30, 2013 | 97.93 Mn |